Snapshot from Jul 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / GE HealthCare and Mayo Clinic...
Tech research collaboration

GE HealthCare and Mayo Clinic theranostics collaboration

Analysis based on 7 articles · First reported Jul 08, 2026 · Last updated Jul 08, 2026

Sentiment
30
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The collaboration may strengthen GE HealthCare's position in theranostics and personalized medicine, potentially boosting its stock. Mayo Clinic's involvement enhances its reputation as a leader in innovative cancer care.

Healthcare Medical Technology Pharmaceuticals
Event Summary

GE HealthCare and Mayo Clinic announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration, a theranostics study to explore personalized radioligand therapy for advanced prostate cancer. The study will use GE HealthCare's StarGuide SPECT/CT technology and MIM Software's MIM LesionID Pro to track tumor response. Mayo Clinic is the first U.S. site to investigate GE HealthCare's next-generation SPECT/CT StarGuide GX technology. The collaboration stems from a 2023 Strategic Radiology Research Alliance.

Entities Involved
stock
GE HealthCare
GE HealthCare is a key collaborator, providing StarGuide SPECT/CT technology and benefiting from potential advancements in theranostics.
Importance 100.0 Sentiment 40.0
priv
MIM Software
MIM Software's MIM LesionID Pro is used in the study, potentially increasing its visibility in theranostics.
Importance 30.0 Sentiment 20.0
per
Andrew Danielsen
Andrew Danielsen, chief business development officer at Mayo Clinic, commented on the collaboration, highlighting its significance.
Importance 20.0 Sentiment 10.0
per
Geoffrey Johnson
Geoffrey Johnson, chair of the Radiopharmaceutical Trial Team at Mayo Clinic, emphasized the potential of theranostics.
Importance 20.0 Sentiment 10.0
per
Sergio Calderón
Sergio Calderón, global general manager of Theranostics at GE HealthCare, expressed support for personalized care.
Importance 20.0 Sentiment 10.0
cnt
United States
The study is based in the U.S., with Mayo Clinic as the first U.S. site to use StarGuide GX technology.
Importance 10.0 Sentiment 5.0
Relationships
GE HealthCare related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.